$11.25
-0.51 (-4.30%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MPLT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 5 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP) · FINRA short interest 1.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophreniaOpen-label · Treatment | Phase 2 | Recruiting | Drug: ML-007C-MA | Schizophrenia | 500 | Feb 2030 | ≤ 1,289 d | 2026-08-13 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisNCT07459660To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with ADOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: ML-007C-MA | Psychosis Associated With Alzheimer's Disease | 210 | Mar 2029 | ≤ 955 d | 2026-08-07 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisNCT06887192Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ML-007C-MA, Placebo | Psychosis Associated With Alzheimer's Disease | 300 | Dec 2027 | ≤ 499 d | 2026-07-29 |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)NCT05889273Frequency of occurrence of treatment-emergent adverse events (TEAEs).Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: ML-004 (IR)/(ER) tablet | Autism Spectrum Disorder | 120 | Nov 2027 | ≤ 468 d | 2026-07-20 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, ML-007C-MA BID, ML-007C-MA QD | Schizophrenia | 307 | 2026-06-04actual | — | 2026-07-09 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)NCT05081245Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ML-004 (IR)/(ER) tablet, ML-004 Placebo | Autism Spectrum Disorder | 168 | 2026-03-10actual | — | 2026-05-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19